FT News Briefing cover image

Draghi urges EU to abandon unanimity requirement

FT News Briefing

00:00

Biogen's Aduhelm Controversy and Market Reactions

This chapter examines the repercussions Biogen faces after the troubled launch of its Alzheimer's drug, Aduhelm, which has led to projected losses over a billion dollars. Additionally, it discusses the broader effects of rising interest rates on the stock market, particularly concerning tech stocks and hedge funds.

Play episode from 05:07
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app